MARKET

MDXG

MDXG

MIMEDX GROUP
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.30
+0.22
+2.42%
Closed 16:00 05/13 EDT
OPEN
9.18
PREV CLOSE
9.08
HIGH
9.56
LOW
9.06
VOLUME
444.01K
TURNOVER
--
52 WEEK HIGH
12.87
52 WEEK LOW
3.350
MARKET CAP
1.04B
P/E (TTM)
-11.4237
1D
5D
1M
3M
1Y
5Y
8-K: MIMEDX GROUP, INC.
(EDGAR Online via COMTEX) -- false 0001376339 0001376339 2021-05-12 2021-05-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 1d ago
MIMEDX Reminds Shareholders to Vote at the Upcoming Annual Meeting
Vote FOR MIMEDX's Experienced and Highly Qualified Directors and Governance Enhancement Proposals
GlobeNewswire · 1d ago
Regenerative Medicine Market Size to Reach Revenues of over USD 23.7 Billion by 2027
May 12, 2021 (Market Insight Reports) -- The new report “Regenerative Medicine Market Size, Share & Growth Analysis By Product (Gene Therapies, Cell...
Market Insight Reports · 1d ago
Biological Implants Market Growth 2021 to 2026, Share, Global Industry Size, Trends, Emerging Factors, Demands, Key Players, Emerging Technologies and Potential of Industry.
May 12, 2021 (The Expresswire) -- Global "Biological Implants Market" (2021-2026) discusses the report additionally centres around worldwide significant...
The Express Wire · 1d ago
Global Amniotic Membrane Market 2021-2025 with Top-Countries Data And Covid-19 Analysis, Industry Insights by Share, Emerging Trends, Regional Analysis, Segments, Prime Players, Drivers, Growth Factor and Foreseen
May 12, 2021 (The Expresswire) -- Global “Amniotic Membrane Market” Report 20212025 covers the worldwide and regional market with an in-depth analysis ofthe...
The Express Wire · 2d ago
MiMedx issued patent for placental tissue for cardiac damage
MiMedx Group (MDXG) has been issued a patent covering placental tissue composition for treating cardiac tissue damage.The company uses dehydrated amniotic tissue and placental-based tissue for wound and burn care,
Seekingalpha · 2d ago
MiMedx Group Shares Quite; Co Granted U.S. Patent Titled 'Placental tissue composition for for treating cardiac tissue damage'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=31&f=G&l=50&co1=AND&d=PTXT&s1=%22**%22&OS=
Benzinga · 2d ago
MDXG: Multiple Readouts This Summer
By John Vandermosten, CFA NASDAQ:MDXG
Benzinga · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MDXG. Analyze the recent business situations of MIMEDX GROUP through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MDXG stock price target is 18.00 with a high estimate of 18.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 132
Institutional Holdings: 45.05M
% Owned: 40.33%
Shares Outstanding: 111.72M
TypeInstitutionsShares
Increased
1
111.32K
New
89
36.02M
Decreased
6
145.44K
Sold Out
1
200
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.35%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Independent Director
M. Kathleen Behrens Wilsey
Chief Executive Officer/Director
Timothy Wright
Chief Financial Officer
Peter Carlson
Executive Vice President
Rohit Kashyap
Executive Vice President
Robert Stein
Senior Vice President/Chief Accounting Officer
William Phelan
Senior Vice President/Director of Investor Relations
Jack Howarth
Senior Vice President
Scott Turner
Chief Compliance Officer
Mark Graves
General Counsel/Secretary
William Hulse
Director
Phyllis Gardner
Director
Charles Koob
Independent Director
James Bierman
Independent Director
Charles Evans
Independent Director
William Hawkins
Independent Director
K. Todd Newton
Independent Director
Martin Sutter
Independent Director
Neil Yeston
Independent Director
M. Behrens Wilsey
Independent Director
J. Dewberry
No Data
  • All
  • Financials
  • Insiders
More
About MDXG
MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Webull offers kinds of MiMedx Group Inc stock information, including NASDAQ:MDXG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDXG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDXG stock methods without spending real money on the virtual paper trading platform.